Back to Search
JAE KIM, MD
MD
Family Medicine Physician
NPI: 1841264918IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
A38875(CA)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
OTHER
Class of 1971
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
PMID 14707118·J Exp Med·2004
4-observational
Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies.
PMID 19536770·Head Neck·2010
5-case
Myeloid-related protein 8/14 levels in children with obstructive sleep apnoea.
PMID 19608587·Eur Respir J·2010
8-other
Interictal metabolic changes in episodic migraine: a voxel-based FDG-PET study.
PMID 19489887·Cephalalgia·2010
8-other
Race and ethnicity correlate with survival in patients with gastric adenocarcinoma.
PMID 19622590·Ann Oncol·2010
8-other
Volar percutaneous screw fixation for scaphoid waist delayed union.
PMID 19669847·Clin Orthop Relat Res·2010
8-other
Selective oxidation of tetralin over a chromium terephthalate metal organic framework, MIL-101.
PMID 19662247·Chem Commun (Camb)·2009
8-other
Linking genetically defined neurons to behavior through a broadly applicable silencing allele.
PMID 19679071·Neuron·2009
7-preclinical
Impact of the TCR signal on regulatory T cell homeostasis, function, and trafficking.
PMID 19668367·PLoS One·2009
7-preclinical
Changes of higher-order aberrations with the use of various mydriatics.
PMID 19663926·Ophthalmic Physiol Opt·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 565 KERN ST
SHAFTER, CA 93263 - Phone
- (661) 746-4937
Quick Facts
- NPI
- 1841264918
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 55
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile